QT间期延长综合征相关药物的合理应用及防治概述

蓝晓红,周永刚

中国药学杂志 ›› 2015, Vol. 50 ›› Issue (10) : 829-833.

PDF(920 KB)
中国药学杂志
PDF(920 KB)
中国药学杂志 ›› 2015, Vol. 50 ›› Issue (10) : 829-833. DOI: 10.11669/cpj.2015.10.001
综述

QT间期延长综合征相关药物的合理应用及防治概述

  • 蓝晓红,周永刚*
作者信息 +

Progress of Reasonable Application and Control in Long QT Syndrome Associated with Drugs

  • LAN Xiao-hong,ZHOU Yong-gang*
Author information +
文章历史 +

摘要

笔者从QT间期延长综合征(long QT syndrome，LQTS)的临床特征、机制与影响因素、药物相关性QT间期延长综合征及临床对其防治的国内外研究进展作一综述，提出临床药师需要关注易致QT间期延长的药物使用，预防临床发生药物致急性心律失常事件等，以促进临床合理用药、提高药物的安全性。

Abstract

This article has made an review including definition of drugrelated long QT interval， clinical features， mechanisms and influencing factors， prevention and treatment of drugrelated QT long syndrome， and its clinical research progresses.It is proposed that clinical pharmacists need to focus more attention on QT prolongation drugsIt can prevent acute arrhythmic events，and promote rationality and safety of drug

关键词

QT间期延长综合征 / 尖端扭转型室性心动过速 / 药物相互作用

Key words

long QT syndrome / torsade de pointes / drug interaction

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
蓝晓红,周永刚. QT间期延长综合征相关药物的合理应用及防治概述[J]. 中国药学杂志, 2015, 50(10): 829-833 https://doi.org/10.11669/cpj.2015.10.001
LAN Xiao-hong,ZHOU Yong-gang. Progress of Reasonable Application and Control in Long QT Syndrome Associated with Drugs[J]. Chinese Pharmaceutical Journal, 2015, 50(10): 829-833 https://doi.org/10.11669/cpj.2015.10.001
中图分类号： R969.3   

参考文献

[1] DESSENENNE F.La tachycardieventriculaireadeux foyers opposes variables.Arch Mal Coeur Vaiss,1966,59: 263-272.
[2] DANIEL L. ICH E14: A new global regulatory guideline on clinical evaluation of cardiac safety for new drug development programs.Chin J Clin Pharmacol Ther(中国临床药理学与治疗学),2006,11(1):116-120.
[3] Arrhythmic Working Group of Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology, Editorial Board of Chinese Journal of Cardiac Pacing and Electrophysiology.Task force recommendations for prevention and treatment of acquired long QT syndrome.Chin J Cardiol(中华心血管病杂志),2010,38(11):961-969.
[4] CAO G Y, ZHANG J, XI Y W. Update of thorough QT/QTc approach and the QTc findings of quinolone antibiotics.Chin J Clin Pharmacol Ther(中国临床药理学与治疗学), 2014,2(3):179-182.
[5] DREW B J,AEKERMAN M J,FUNK M,et al.Prevention of torsade de pointes in hospital settings:Ascientific statement from the American Heart AssociatiOn and the American College of Cardiology Foundation. Circulation,2010,121(8):1047-1060.
[6] WOOSLEY R L,CHEN Y, FREIMAN J P,et al.Mechanism of the cardiotaxicactions of tedenadine. JAMA,1993,269(12):1532-1536.
[7] DE BRUIN M L,LANGENDIJK P N,KOOPMANS R P,et al.In-hospital cardiac arrest is associated with use of nonantiarrhythmicQTc-prolonging drugs.Br J Clin Phamacol,2007,63(2):216-223.
[8] SHE F, LI H Y.Cardiac safety evaluation of pharmaceuticals and thorough QT/QTc study. Chin J Clin Pharmacol(中国临床药理学杂志), 2011,5(3):74-77.
[9] ZHANG X X,ZHANG L M,ZHENG Q M,et al. Impact on QTc Interval and Safety Evaluation of Amiodarone Injection for Inpatients.Chin J Pharmacovigilance(中国药物警戒),2013,10(3):13-16.
LI G,CHENG G,WU J, et al. Drug-induced long QT syndrome in women. Adv Ther, 2013,30(9):793-802.
ZHOU C C,WANG H. Clinical research of QT interval prolongation. Med Recapit(医学综述),2011,17(15):79-81.
ARMAHIZER M J, SEYBERTA L, SMITHBURGEP L. et al. Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. J Critical Care,2013(28):243-249.
WANG J K,YU Z X,CUI C Z. Mechanism of drug-induced torsade de pointes: An experimental study in dogs.J Southern Med Univ(南方医科大学学报), 2013,33(7):161-164.
ZHAO Y H,SHEN D L.Verification of the prescriptions caused the drug-induced QT prolongation and torsade de pointes. World Clinical Drugs, 2013,34(5):65-68.
TAY K Y, EWALD M B, BOURGEOIS F T. Use of QT prolonging medications in US emergency departments, 1995-2009. Pharmacol Epidemiol Drug Saf,2014,23(1):9-17.
SHAH R R. Drug-induced QT interval prolongation: Does ethnicity of the thorough QT study population matter.Br J Clin Pharmacol,2013, 75(2):347-358.
RODEN D M. Risk and benefits of antiarrhythmic therapy. N Engl J Med, 1994, 331(12): 785-791.
OBERG K C, O′TOOLE M F, GALLASTEGUI J L, et al. "Late" proarrhythmia due to quinidine.Am J Cardiol, 1994, 74(2): 192- 193.
BAUMAN J L, BAUERNFEIND R A,HOFF J V. Torsades de po intes due to quinidine: Observationin 31 patients. Am Heart J, 1984, 107(3): 425-430.
BORIANI G, BIFFI M, DE SIMONE N, et al. Repolarization changes in a double-blindcrossover study of dofetilide ver sus sotalol in the treatment of ventricular tachycardia.Pacing Clin Electrophysiol, 2000, 23(11 Pt 2): 1935-1938.
HAVEKAMP W,MAR-TINEZ R A,HIEF C, et al. Efficacy and safety of d,l-sotalol inpatients with ventricular tachycardia and in survivors of cardiac arrest. J Am Coll Cardiol, 1997, 30(2): 487-495.
HOHNLOSER S H. Proarrhythmia with class ó anti arrhythmic drugs: Types, risks, and management . Am J Cardiol, 1997, 80(8A): 82-89.
CAZZARA R. Amiodarone and torsade de pointes[. Ann Intern Med, 1989, 111(7): 549-551.
LI Y T, ZHANG C T, LU Z Y.Effects of amiodarone and sotalol on repolarization heterogeneity .Chin J Cardiac Arrhythmias(中华心率失常学杂志), 2000,4(4): 284-288.
ANTZATEVITH C,SUN Z,ZHANG Z,et al. Cellular and ionic mechanisms underlying erythromycin induced long QT intervals and tor sades de pointes.J Am Coll Cardiol, 1996, 28(7): 1836-1848.
NATTEL S, RANGER S, TALAJIC M, et al. Erythromycin-induced long QT syndrome: Concordance with quinidine andunderlying cellular electrophysiologic mechanism.Am J Med, 1990, 89(2): 235-238.
JAILLON P,MORGANROTH J, BRUMPT I, et al. Overview of electrocardiographic and cardiovascularsafety data forsparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother, 1996, 37(suppl A): 161-167.
SLAUGHTE R R, EDWARDS D. Recent advance: The cytochrome P450 enzymes. Ann Pharmacother, 1995, 29(6): 619-624.
DUMAINE R,ROY M, BROWN A. Blockade of HERG and Kv1.5 by ketoconazole. J Pharmacol Exp Ther, 1998,286(2): 727-735.
YAP Y G, CAMM A J. Arrhythmogenic mechanisms of non-sedating antihistamines.Clin Exp Allergy, 1999, 29(suppl 3): 174-181.
RAYMOND L W,CHEN Y W, JOOL P, et al.Mechanism of the cardiotoxic actions of terfenadine. JAMA, 1993, 269(12): 1532-1536.
GLASSMAN A H, BIGGER J T J R. Antipsychotic drugs: Prolonged QTc interval, torsadede pointes, and sudden death. Am J Psychiatry, 2001, 158(11): 1774-1782.
DANIEL W A, SYREK M,HADUCH A, et al. Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants.Br J Pharmacol,2000, 131(2): 287-295.
WYSOWSKI D K, CORKEN A, GALLO-TORRES H, et al. Postmarketing reports of QT prolongation andventricular arrhythmia in association with cisapride and food anddrug administration regulatory actions. Am J Gastroenterol, 2001, 96(6) :1698-1703.
MOHAMMED S, ZHOU Z, GONG Q, et al. Blockade of theHERG human cardiac K+ channel by the gastro intestinal prokinetic agent cisapride . Am J Physiol,1997, 273(5):2534-2538.
GUTGESELL H, ATKINS D, BARST R, et al. Cardiovascular monitoring of children andadolescents receiving psychotropic drugs: A statement for healthcare professionals from the committee on congenital cardiac defects, council on cardiovascular diseasein the young, American Heart Association[. Circulation, 1999, 99(7): 979-982.
TISDALE J E,JAYNES H A, KINGERY J R, et al. Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients . Circ Cardiovasc Qual Outcomes, 2013,6(4):479-487.
GU R J.The cardiotoxicity of second-generation antihistamines. Chin Pharm J(中国药学杂志),2002,37(2): 90-93.
PDF(920 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉